Retinal Physician Insider: Recent Episodes
Retinal Physician Insider
Chief Medical Editor Peter Kaiser, MD, will interview key retina surgeons regarding their clinical experience and honest conversations on managing patients during COVID, ensuring adherence to treatment regimens, how they talk to patients and handling durability during the pandemic.
Description: Peter Kaiser, MD and Yasha Modi, MD discuss treatment of non-proliferative diabetic retinopathy in the absence of diabetic macular edema.
Peter Kaiser, MD and Caroline Baumal, MD discuss the history and practice of treatment for diabetic retinopathy.
Peter Kaiser, MD and Carol Regillo, MD, FACS discuss the port delivery system and how it impacts treatment of wet AMD.
Peter Kaiser, MD and Christina Weng, MD discuss treatment options in the Covid era, AMD, and the durability of these treatments.
Peter Kaiser, MD, and Rishi Singh, MD assess treatment goal challenges with persistent fluid, accompanied with inability to extend injection intervals.
Peter Kaiser, MD, and Carl Awh, MD discuss what retina specialists can expect with the new Port Delivery System from Genentech.
Peter Kaiser, MD, and Tarek S. Hassan, MD, discuss tips and tricks for closing complicated macular holes.
Peter Kaiser, MD, and Jeffrey Heier, MD, discuss dramatic changes that can influence treatment and care in high risk cases of diabetic retinopathy.
Peter Kaiser, MD, and Rishi Singh, MD, assess new therapies and clinical trials for age-related macular degeneration.
Peter Kaiser, MD, and Michael Singer, MD, discuss strategies choosing an anti-VEGF treatment based on patients’ personal needs, how to handle non-responders, and what do to when inflammation is a concern.
Peter Kaiser, MD, and Timothy Murray, MD, MBA, discuss the HAWK and HARRIER phase 3 studies evaluating the safety and efficacy of brolucizumab for wet AMD.
Peter Kaiser, MD, and Jeffrey Heier, MD, examine the findings of the Novartis-appointed Safety Review Committee’s independent assessment of post-marketing cases of inflammation following the approval of brolucizumab.